{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:26:35Z","timestamp":1763018795846},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/coc.0b013e31819142c7","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T09:48:55Z","timestamp":1242899335000},"page":"429-431","source":"Crossref","is-referenced-by-count":0,"title":["Obtaining Routine Blood Cultures During Interleukin-2-Containing Therapy Is Unnecessary"],"prefix":"10.1097","volume":"32","author":[{"given":"Michael V.","family":"Jaglal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian A.","family":"Laber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forest W.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Chesney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goetz H.","family":"Kloecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 7","key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.33077","article-title":"Interleukin-2: clinical applications.","volume":"29","author":"Atkins","year":"2002","journal-title":"Semin Oncol"},{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.hoc.2006.02.005","article-title":"Immunotherapy of melanoma.","volume":"20","author":"Rietschel","year":"2006","journal-title":"Hematol Oncol Clin North Am"},{"key":"R3-18-20210128","first-page":"2611","article-title":"Practical guidelines for the management of biochemotherapy-related toxicity in melanoma.","volume":"7","author":"Buzaid","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","article-title":"Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.","volume":"16","author":"Legha","year":"1998","journal-title":"J Clin Oncol"},{"key":"R5-18-20210128","first-page":"3075","article-title":"A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.","volume":"8","author":"Atkins","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R6-18-20210128","first-page":"2201","article-title":"A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.","volume":"6","author":"McDermott","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/cbr.2005.20.11","article-title":"Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.","volume":"20","author":"Quan","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/1097-0142(19910315)67:6<1570::AID-CNCR2820670619>3.0.CO;2-V","article-title":"Association of interleukin-2 therapy with staphylococcal bacteremia.","volume":"67","author":"Richards","year":"1991","journal-title":"Cancer"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/0003-4819-112-2-102","article-title":"Nosocomial sepsis associated with interleukin-2.","volume":"112","author":"Snydman","year":"1990","journal-title":"Ann Intern Med"},{"key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0272-2712(18)30390-1","article-title":"Clinical importance of blood cultures.","volume":"14","author":"Weinstein","year":"1994","journal-title":"Clin Lab Med"},{"key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/clinids\/23.1.40","article-title":"Current blood culture methods and systems: clinical concepts, technology, and interpretation of results.","volume":"23","author":"Weinstein","year":"1996","journal-title":"Clin Infect Dis"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00000421-200908000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:51:11Z","timestamp":1618033871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-200908000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31819142c7","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}